LABORATORY RESEARCH Inhibition of O-GlcNAc Transferase Activity Reprograms Prostate Cancer Cell Metabolism Scientists showed that inhibition of O-GlcNAc transferase activity inhibits the proliferation of prostate cancer cells, leads to sustained loss of c-MYC and suppresses the expression of CDK1, elevated expression of which predicts prostate cancer recurrence. [Oncotarget] Full Article Exosomes Confer Pro-Survival Signals to Alter the Phenotype of Prostate Cells in Their Surrounding Environment Researchers hypothesized that exosomes play a pivotal role in cell-cell communication in the local tumor microenvironment, conferring activation of numerous survival mechanisms during prostate cancer (PCa) progression and development of therapeutic resistance. Their in vitro results demonstrate that PCa derived exosomes significantly reduce apoptosis in LNCaP and RWPE-1 cells increase cancer cell proliferation and induce cell migration. [Oncotarget] Full Article Evaluation of Polymer Shielding for Adenovirus Serotype 6 (Ad6) for Systemic Virotherapy against Human Prostate Cancers Lower seroprevalence Ad6 was tested as a systemic therapy for prostate cancer. Ad5 and Ad6 were injected intravenously a single time in nude mice bearing human prostate tumors, and toxicity and efficacy were assessed. [Mol Ther] Full Article EC-70124, a Novel Glycosylated Indolocarbazole Multi-Kinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB Researchers showed that EC-70124 blocked concomitantly NF-κB and STAT3 in prostate cancer cells and particularly prostate cancer stem cells, which exhibited over-activation of these transcription factors. [Mol Cancer Ther] Abstract Gene Expression Signatures Associated with Suppression of TRAMP Prostate Carcinogenesis by a Kavalactone-Rich Kava Fraction Scientists evaluated the chemopreventive effect of a kavalactone-rich Kava fraction B, free of flavokavains, on carcinogenesis in a transgenic adenocarcinoma of mouse prostate (TRAMP) model and characterized the prostate gene expression signatures. [Mol Carcinog] Abstract A Transcriptional Target of Androgen Receptor, miR-421 Regulates Proliferation and Metabolism of Prostate Cancer Cells This study identified an androgen receptor (AR)-repressed microRNA, miR-421, in prostate cancer. Expression of miR-421 was significantly suppressed by androgen treatment, and correlated to AR expression in different prostate cancer cell lines. [Int J Biochem Cell Biol] Abstract Phosphoproteome Analysis Demonstrates the Potential Role of THRAP3 Phosphorylation in Androgen-Independent Prostate Cancer Cell Growth Investigators performed a comparative phosphoproteome analysis using a prostate cancer cell line, LNCaP, and an LNCaP-derived androgen-independent cell line, LNCaP-AI, to identify phosphoproteins involved in this mechanism. [Proteomics] Abstract De Novo Steroid Biosynthesis in Human Prostate Cell Lines and Biopsies The authors performed comparative gene expression analyses between various prostate cell lines and biopsies, including normal, hyperplastic, cancerous, and androgen-deprived prostate cells lines, as well as normal, benign prostate hyperplasia, prostate cancer, and castration-resistant prostate cancer human specimens. [Prostate] Abstract CLINICAL RESEARCH Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer Men with pathologically confirmed prostate cancer and radiologic progression of bone lesions in the 28 days prior to randomization were assigned to receive abituzumab or or placebo every three weeks in combination with luteinizing hormone-releasing hormone agonist/antagonist therapy. [Clin Cancer Res] Abstract Severe Neutropenia during Cabazitaxel Treatment Is Associated with Survival Benefit in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post-Hoc Analysis of the TROPIC Phase III Trial Data from the experimental arm of the TROPIC Phase III trial which randomly assigned men with mCRPC to cabazitaxel or mitoxantrone every three weeks, both combined with daily prednisone, were analysed. [Eur J Cancer] Abstract |